Needham & Company LLC Reiterates “Buy” Rating for Lucid Diagnostics (NASDAQ:LUCD)

Needham & Company LLC reissued their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a $2.50 price objective on the stock.

Other equities analysts also recently issued research reports about the stock. Ascendiant Capital Markets lowered their target price on shares of Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating for the company in a research note on Tuesday, September 10th. Canaccord Genuity Group raised Lucid Diagnostics to a “strong-buy” rating in a research report on Tuesday, August 13th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research report on Tuesday, August 13th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Lucid Diagnostics presently has an average rating of “Buy” and a consensus target price of $3.69.

Lucid Diagnostics Stock Performance

Lucid Diagnostics stock opened at $0.99 on Thursday. The firm has a market cap of $58.56 million, a price-to-earnings ratio of -0.87 and a beta of 1.41. Lucid Diagnostics has a 52-week low of $0.63 and a 52-week high of $1.58. The firm has a 50 day moving average price of $0.87 and a two-hundred day moving average price of $0.85.

Institutional Investors Weigh In On Lucid Diagnostics

An institutional investor recently raised its position in Lucid Diagnostics stock. Virtu Financial LLC raised its holdings in Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,671 shares of the company’s stock after buying an additional 13,835 shares during the period. Virtu Financial LLC owned about 0.07% of Lucid Diagnostics worth $28,000 as of its most recent filing with the Securities and Exchange Commission. 74.01% of the stock is owned by institutional investors and hedge funds.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.